Aridis Pharmaceuticals Announces Exclusive License Of Suvratoxumab Phase 3-Ready Monoclonal Antibody From AstraZeneca; Highlights Uo To $30M Funding From EU Commission For Phase 3 Trial
Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (NASDAQ:AZN) to in-license the late stage monoclonal antibody candidate,